Shared Mechanisms and Integrated Management of Post-Stroke Pain and Depression: A Comprehensive Review
Open Access
- 17 November 2025
- journal article
- review article
- Published by Springer Nature in Pain and Therapy
- Vol. 15 (1) , 19-39
Abstract
Post-stroke pain (PSP) and post-stroke depression (PSD) represent two major neuropsychiatric complications that frequently co-occur, with comorbidity rates ranging from 34 to 65.6%. Despite their high prevalence and profound impact on functional recovery and quality of life, the shared mechanisms and optimal management of this complex comorbidity remain poorly understood. We conducted a systematic review of clinical and preclinical evidence to explore the epidemiological characteristics, diagnostic challenges, neurobiological underpinnings, and therapeutic strategies for comorbid PSP and PSD. Special emphasis was placed on neuroinflammatory cascades, glial cell dysfunction, monoaminergic system dysregulation, and maladaptive neural circuit remodeling. We found PSP and PSD exhibit overlapping pathophysiological mechanisms, including microglial activation, astrocytic reactivity, pro-inflammatory cytokine release (e.g., TNF-α, IL-1β, IL-6), and dysregulation of cortico-limbic circuits involving the anterior cingulate cortex, amygdala, and ventral tegmental area. Pharmacotherapies such as serotonin-norepinephrine reuptake inhibitors (SNRIs) and NMDA receptor antagonists (e.g., ketamine), as well as neuromodulation approaches (e.g., repetitive transcranial magnetic stimulation [rTMS], transcranial direct current stimulation [tDCS]), demonstrate efficacy in both conditions, likely through anti-inflammatory and neural circuit-modulating effects. We speculate that the comorbidity of PSP and PSD is underpinned by convergent neuroimmune and neural circuit mechanisms. Targeting these shared pathways—such as with cytokine inhibitors, glial modulators, and circuit-specific neuromodulation—holds promise for developing integrated, mechanism-based therapies. Future research should prioritize multimodal treatment strategies tailored to the neurobiological signatures of this debilitating post-stroke syndrome. Infographic available for this article.Keywords
Funding Information
- Scientific Research Fund of Zhejiang University (XY2024028)
This publication has 132 references indexed in Scilit:
- Prevalence of Depression and Anxiety Among Adults With Chronic PainJAMA Network Open, 2025
- A Novel Endoplasmic Reticulum‐Targeted Metal–Organic Framework–Confined Ruthenium (Ru) Nanozyme Regulation of Oxidative Stress for Central Post‐Stroke PainAdvanced Healthcare Materials, 2023
- Effects of the Notch Signaling Pathway on Secondary Brain Changes Caused by Spinal Cord Injury in MiceNeurochemical Research, 2022
- The advances of post-stroke depression: 2021 updateJournal of Neurology, 2021
- Repetitive transcranial magnetic stimulation for post-stroke depression: a randomised trial with neurophysiological insightJournal of Neurology, 2020
- Protective effects of dihydromyricetin on primary hippocampal astrocytes from cytotoxicity induced by comorbid diabetic neuropathic pain and depressionPurinergic Signalling, 2020
- Dihydromyricetin exerts a rapid antidepressant-like effect in association with enhancement of BDNF expression and inhibition of neuroinflammationPsychopharmacology, 2017
- Psychiatric co‐morbidities in patients with chronic peripheral neuropathic pain: A multicentre cohort studyEuropean journal of pain, 2013
- Escitalopram and Problem-Solving Therapy for Prevention of Poststroke DepressionJAMA, 2008
- Clinical study of 99 patients with pure sensory strokeJournal of Neurology, 2005